Extended Data Figure 4: Depletion of CD36 inhibits metastatic initiation and progression.
From: Targeting metastasis-initiating cells through the fatty acid receptor CD36
a, BLI signal quantifications (*P = 0.01, two-tailed t-test) and frequency of developed tumours (*P = 0.04, two-tailed Fisher’s exact test) of PMSCV-EV and CD36–overexpressing tumours from VDH-00 primary cell line (PMSCV-EV, n = 7; CD36OE, n = 8). b, BLI monitoring of tumours from FaDu cell line transduced with either PLKO or shRNA CD36 (two independent experiments: exp1. and exp.2, n = 5 mice per group). Graphs show the frequency of developed tumours, and BLI signal quantification (metastasis lymph node, *P = 0.05; metastasis lung, **P = 0.002; two-tailed t-test). c, d, Flow cytometry analysis of tumours from OSCC cells transduced with PLKO or shRNA CD36#99. Numbers indicate the percentages of CD44bright CD36+, CD44bright CD36– or CD44dim cells in the represented gate (n = 6 animals per group). e, Relative RNA levels of CD36 in SCC-25 parental and shRNA CD36 cells, determined by RT–qPCR analysis using TaqMan gene expression assay. Human β-2-microglobulin was used as internal control gene (n = 3 biological replicates, ****P < 0.005, two-tailed t-test). Data in a, b, e, are given as the mean ± s.e.m. f, Representative images of lungs from mice transplanted with PLKO or shRNACD36 FaDu cells (PLKO, n = 5 mice; shRNA CD36#99, n = 5 mice). g, Haematoxylin and eosin staining of metastatic lymph nodes from cells transduced with PLKO or shRNA Cd36. h, Representative haematoxylin-eosin staining of primary tumours from transplanted SCC-25 cells transduced with PLKO or Cd36 shRNA (n = 5 mice per group). Source data from mouse experiments are in Supplementary Information.
